ArticleThe Journal of investigative dermatology2015
Inhibition of human melanoma growth by a non-cardioselective β-blocker.
Article in The Journal of investigative dermatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 64 citations in OpenAlex.
- Preclinical Evaluation of Labetalol for Cutaneous Melanoma Drug Repurposing: Cytotoxic Activity in A375 Cells and Mitochondria-Associated Apoptotic Signaling.Medicina (Kaunas, Lithuania) · 2026Article
- Antitumour Effects of β-Blockers: A Narrative Review of the Literature.Current issues in molecular biology · 2026Review
- Antihypertensive Drugs as Potential Repositioning Options for Melanoma: A Map of Pre-Clinical Evidence.Diseases (Basel, Switzerland) · 2026Review
- Recent advances in drug repositioning and rediscovery for different therapeutic activities utilizing updated technological approaches.Molecular diversity · 2026Review
- Activation of α2-adrenergic receptors as a therapeutic strategy for immune rejection in post-surgery osteosarcoma recurrence treatment.Journal of orthopaedic translation · 2026Article
- Article
- Bioadhesive Eudragit RLPharmaceutics · 2025Article
- Stress regulatory hormones and cancer: the contribution of epinephrine and cancer therapeutic value of beta blockers.Endocrine · 2025Review
- Neuroimmune Interactions and Their Role in Immune Cell Trafficking in Cardiovascular Diseases and Cancer.International journal of molecular sciences · 2025Review
- Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence.European heart journal · 2024Review
- Role of stress in the pathogenesis of cancer (Review).International journal of oncology · 2023Review
- Review
- Trial watch: beta-blockers in cancer therapy.Oncoimmunology · 2023Article
- Surgical Stress and Cancer Progression: New Findings and Future Perspectives.Current oncology reports · 2022Review
- Drug repurposing-an emerging strategy in cancer therapeutics.Naunyn-Schmiedeberg's archives of pharmacology · 2022Review
- New Potential Agents for Malignant Melanoma Treatment-Most Recent Studies 2020-2022.International journal of molecular sciences · 2022Review
- Crosstalk between β2- and α2-Adrenergic Receptors in the Regulation of B16F10 Melanoma Cell Proliferation.International journal of molecular sciences · 2022Article
- β-Adrenergic signaling in skin cancer.FASEB bioAdvances · 2022Review
- Role of the parasympathetic nervous system in cancer initiation and progression.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, retrospective studies provided conflicting results on the benefit of β-adrenoceptor-blockers (β-blockers) on melanoma progression. Most of these studies did not define the β-blocker used, making it difficult to understand the source of discrepancies between results. Therefore, we investigated the effect of non-cardioselective and cardioselective β-blockers on melanoma progression at the cellular, molecular, and tumor levels. Here we show that the non-cardioselective β-blocker propranolol hydrochloride (propranolol) inhibits proliferation and induces apoptosis in primary cell cultures derived from a primary and a metastasis of human melanoma and in melanoma cell lines. In contrast, the cardioselective β-blocker metoprolol tartrate hardly affects melanoma cell survival or proliferation. We further highlight that a daily treatment with propranolol slows down tumor development in immunodeficient mice transplanted with human melanoma cells. RNA microarrays, quantitative PCR, and histochemistry analyses showed that propranolol regulates the expression of different genes involved in tumor angiogenesis, cell death, or proliferation. Thus, our results suggest that non-cardioselective β-blockers affect melanoma progression, and bring first clues about the pathways involved in this antitumor effect.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.